Sunovion Pharmaceuticals Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Sunovion Pharmaceuticals Inc. – Product Pipeline Review – 2016’, provides an overview of the Sunovion Pharmaceuticals Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sunovion Pharmaceuticals Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Sunovion Pharmaceuticals Inc.

The report provides overview of Sunovion Pharmaceuticals Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Sunovion Pharmaceuticals Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Sunovion Pharmaceuticals Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Sunovion Pharmaceuticals Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Sunovion Pharmaceuticals Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Sunovion Pharmaceuticals Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Sunovion Pharmaceuticals Inc. Snapshot 6

Sunovion Pharmaceuticals Inc. Overview 6

Key Information 6

Key Facts 6

Sunovion Pharmaceuticals Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

Sunovion Pharmaceuticals Inc. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Sunovion Pharmaceuticals Inc. - Pipeline Products Glance 14

Sunovion Pharmaceuticals Inc. - Late Stage Pipeline Products 14

Pre-Registration Products/Combination Treatment Modalities 14

Phase III Products/Combination Treatment Modalities 15

Sunovion Pharmaceuticals Inc. - Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Sunovion Pharmaceuticals Inc. - Early Stage Pipeline Products 18

IND/CTA Filed Products/Combination Treatment Modalities 18

Preclinical Products/Combination Treatment Modalities 19

Discovery Products/Combination Treatment Modalities 20

Sunovion Pharmaceuticals Inc. - Drug Profiles 21

eslicarbazepine acetate 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

dasotraline 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

glycopyrrolate 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

DSP-2230 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

DSP-3748 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

SEP-363856 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

SEP-360 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

SEP-39 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Small Molecule 1 for Neuropsychiatric Disorders 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Small Molecule for Neuropsychiatric Disorders 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Small Molecule to Inhibit D-amino acid oxidase for Neuropathic Pain, Inflammatory Pain and Memory Impairment 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

EP-103 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Small Molecules for Central Nervous System Disorders 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Small Molecules to Modulate GPCR and Ion Channel for Psychiatric Disorders 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Sunovion Pharmaceuticals Inc. - Pipeline Analysis 39

Sunovion Pharmaceuticals Inc. - Pipeline Products by Target 39

Sunovion Pharmaceuticals Inc. - Pipeline Products by Route of Administration 41

Sunovion Pharmaceuticals Inc. - Pipeline Products by Molecule Type 42

Sunovion Pharmaceuticals Inc. - Pipeline Products by Mechanism of Action 43

Sunovion Pharmaceuticals Inc. - Recent Pipeline Updates 45

Sunovion Pharmaceuticals Inc. - Dormant Projects 51

Sunovion Pharmaceuticals Inc. - Discontinued Pipeline Products 52

Discontinued Pipeline Product Profiles 52

dasotraline 52

DSP-1053 52

DSP-8658 52

SEP-228432 52

tecastemizole 52

Sunovion Pharmaceuticals Inc. - Locations and Subsidiaries 53

Head Office 53

Other Locations & Subsidiaries 53

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55

List of Tables

List of Tables

Sunovion Pharmaceuticals Inc., Key Information 6

Sunovion Pharmaceuticals Inc., Key Facts 6

Sunovion Pharmaceuticals Inc. – Pipeline by Indication, 2016 8

Sunovion Pharmaceuticals Inc. – Pipeline by Stage of Development, 2016 10

Sunovion Pharmaceuticals Inc. – Monotherapy Products in Pipeline, 2016 11

Sunovion Pharmaceuticals Inc. – Partnered Products in Pipeline, 2016 12

Sunovion Pharmaceuticals Inc. – Partnered Products/ Combination Treatment Modalities, 2016 13

Sunovion Pharmaceuticals Inc. – Pre-Registration, 2016 14

Sunovion Pharmaceuticals Inc. – Phase III, 2016 15

Sunovion Pharmaceuticals Inc. – Phase II, 2016 16

Sunovion Pharmaceuticals Inc. – Phase I, 2016 17

Sunovion Pharmaceuticals Inc. – IND/CTA Filed, 2016 18

Sunovion Pharmaceuticals Inc. – Preclinical, 2016 19

Sunovion Pharmaceuticals Inc. – Discovery, 2016 20

Sunovion Pharmaceuticals Inc. – Pipeline by Target, 2016 39

Sunovion Pharmaceuticals Inc. – Pipeline by Route of Administration, 2016 41

Sunovion Pharmaceuticals Inc. – Pipeline by Molecule Type, 2016 42

Sunovion Pharmaceuticals Inc. – Pipeline Products by Mechanism of Action, 2016 43

Sunovion Pharmaceuticals Inc. – Recent Pipeline Updates, 2016 45

Sunovion Pharmaceuticals Inc. – Dormant Developmental Projects,2016 51

Sunovion Pharmaceuticals Inc. – Discontinued Pipeline Products, 2016 52

Sunovion Pharmaceuticals Inc., Other Locations 53

Sunovion Pharmaceuticals Inc., Subsidiaries 53

List of Figures

List of Figures

Sunovion Pharmaceuticals Inc. – Pipeline by Top 10 Indication, 2016 8

Sunovion Pharmaceuticals Inc. – Pipeline by Stage of Development, 2016 10

Sunovion Pharmaceuticals Inc. – Monotherapy Products in Pipeline, 2016 11

Sunovion Pharmaceuticals Inc. – Partnered Products in Pipeline, 2016 12

Sunovion Pharmaceuticals Inc. – Pipeline by Top 10 Target, 2016 39

Sunovion Pharmaceuticals Inc. – Pipeline by Route of Administration, 2016 41

Sunovion Pharmaceuticals Inc. – Pipeline by Molecule Type, 2016 42

Sunovion Pharmaceuticals Inc. – Pipeline Products by Top 10 Mechanism of Action, 2016 43

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports